移植診断の世界市場：技術、製品・サービス（装置、試薬、ソフトウェア）、用途、エンドユーザー...市場調査レポートについてご紹介

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
1.3.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Introduction (Page No. – 20)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Opportunity Indicators
2.2.1 Introduction
2.2.2 Demand-Side Analysis
2.2.2.1 Healthcare Expenditure Patterns
2.2.2.2 Rapid Growth in Geriatric Population
2.2.2.3 Rising Incidence and Prevalence of Cancer
2.2.2.4 Growing Burden of Cardiovascular Diseases (CVDs)
2.2.2.5 Increasing Number of Organ Donations and Transplantations
2.2.3 Supply-Side Analysis
2.2.3.1 Number of New Product Launches: Transplant Diagnostics vs. Competitive Technologies
2.2.3.2 Parent Market Analysis: Immunoassay Market
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Research Assumptions
2.5.1 Assumptions

3 Executive Summary (Page No. – 41)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 48)
4.1 Global Transplant Diagnostics Market Overview
4.2 Global Transplant Diagnostics Technology Market, By Region (2016)
4.3 Global Transplant Diagnostics Product and Services Market, By Region (2016-2021)
4.4 Global Transplant Diagnostics Applications Market, By Region (2016-2021)
4.5 Global Transplant Diagnostics Market, By End User (2016–2021)
4.6 Global Transplant Diagnostics Market, By Country (2016–2021)

5 Market Overview (Page No. – 53)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Key Market Drivers
5.3.1.1 Growing Number of Solid Organ, Soft-Tissue, and Stem Cell Transplantation Procedures
5.3.1.2 Technological Advancements in the Field of Hla Typing
5.3.1.3 Increased Funding, Research Grants, and Public-Private Investments
5.3.2 Key Market Restraints
5.3.2.1 High Cost of NGS and PCR-Based Devices
5.3.2.2 Limited Medical Reimbursements for Organ Donation and Transplantation Procedures
5.3.3 Key Market Opportunities
5.3.3.1 Technological Shift From Serological Assays to Gene-Based Hla Profiling
5.3.3.2 Improving Healthcare Infrastructure Across Developing Countries
5.3.4 Key Market Challenges
5.3.4.1 Significant Gap Between Number of Organs Donated and Organs Required Annually

6 Industry Insights (Page No. – 63)
6.1 Introduction
6.2 Value Chain Analysis
6.3 Industry Trends
6.3.1 Integration of Advanced Technologies With Molecular Assay Procedure
6.4 Porter’s Five Forces Analysis
6.4.1 Threat of New Entrants
6.4.2 Threat of Substitutes
6.4.3 Bargaining Power of Suppliers
6.4.4 Bargaining Power of Buyers
6.4.5 Intensity of Competitive Rivalry

7 Transplant Diagnostics Market, By Technology (Page No. – 69)
7.1 Introduction
7.2 Molecular Assays
7.2.1 PCR-Based Molecular Assays
7.2.1.1 Sequence-Specific Primer (SSP)-PCR
7.2.1.2 Sequence-Specific Oligonucleotide (SSO)-PCR
7.2.2 Sequencing-Based Molecular Assays
7.2.2.1 Sanger Sequencing
7.2.2.2 Next-Generation Sequencing (NGS)
7.3 Non-Molecular Assays
7.3.1 Serological Assays
7.3.2 Mixed Lymphocyte Culture (MLC) Assays

8 Transplant Diagnostics Market, By Products & Services (Page No. – 82)
8.1 Introduction
8.2 Reagents and Consumables
8.3 Instruments
8.4 Software and Services

9 Transplant Diagnostics Market, By Application (Page No. – 87)
9.1 Introduction
9.2 Diagnostic Applications
9.3 Research Applications

10 Transplant Diagnostics Market, By End User (Page No. – 92)
10.1 Introduction
10.2 Hospitals and Transplant Centers
10.3 Commercial Service Providers
10.4 Research Laboratories and Academic Institutes

11 Transplant Diagnostics Market, By Region (Page No. – 98)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Rest of Europe (RoE)
11.4 Asia-Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia-Pacific (RoAPAC)
11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. – 128)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Scenario
12.4 Recent Developments
12.4.1 Agreements, Partnerships, and Collaborations
12.4.2 New Product Launches, Approvals, and Product Enhancements
12.4.3 Strategic Acquisitions
12.4.4 Geographic Expansions

13 Company Profiles (Page No. – 136)
13.1 Introduction
13.1.1 Geographic Benchmarking
13.1.2 Strategic Benchmarking
13.1.2.1 Capacity Building and Capability Enhancement
13.2 Thermo Fisher Scientific, Inc.
13.2.1 Business Overview
13.2.2 Products Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.3 Immucor, Inc.
13.3.1 Business Overview
13.3.2 Products Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Olerup SSP AB
13.4.1 Business Overview
13.4.2 Products Offered
13.4.3 Recent Developments
13.4.4 MnM View
13.5 Qiagen N.V.
13.5.1 Business Overview
13.5.2 Products Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Bio-Rad Laboratories, Inc.
13.6.1 Business Overview
13.6.2 Products Offered
13.6.3 Recent Developments
13.6.4 MnM View
13.7 Illumina, Inc.
13.7.1 Business Overview
13.7.2 Products Offered
13.7.3 Recent Developments
13.8 Affymetrix, Inc.
13.8.1 Business Overview
13.8.2 Products Offered
13.8.3 Recent Developments
13.9 F. Hoffmann-La-Roche Limited
13.9.1 Business Overview
13.9.2 Products Offered
13.9.3 Recent Developments
13.10 Luminex Corporation
13.10.1 Business Overview
13.10.2 Products Offered
13.10.3 Recent Developments
13.11 Abbott Laboratories, Inc.
13.11.1 Business Overview
13.11.2 Products Offered
13.11.3 Recent Developments

14 Appendix (Page No. – 171)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports